Kornimate/medical-research-clean huggingface dataset:
bariatric surgery and guided self-help for binge eating disorder

Conditions: Obesity

Summary: to demonstrate the effectiveness of an easily administered intervention (guided self help) aimed at reducing binge eating in patients undergoing bariatric surgery. the investigators hypothesize that patients who have guided self help pre-operatively will have reduced episodes of bingeing pre-operatively compared to those having treatment as usual (bariatric surgery), which will be maintained in the post-operative period, and will be associated with improved weight loss and psychological outcomes after surgery.

binge eating disorder (bed) is distressing and common in patients who present for treatment for obesity. despite this, it is often undiagnosed. patients who have bariatric surgery have improvements in their eating patterns, including binge eating. however there is variability in the degree of weight loss and post-operative complications following bariatric surgery, associated with disordered eating. guided self help for bed (gsh) is a treatment which, like bariatric surgery, is effective in reducing the number of binge episodes in people who binge eat. it is not known whether gsh prior to surgery, in patients undergoing bariatric surgery has any additional benefit for reducing bingeing, or improving weight loss in these patients.

Eligibility criteria:
inclusion criteria: * obese (bmi \>28 kg/m2) * pursuing bariatric surgery exclusion criteria: * any illnesses which make the patient unsuitable * if the patient is taking any medication which makes them unsuitable * if the patient is pregnant or breast feeding * if the patient has donated blood in the last three months * if the patient has a history of alcoholism or substance dependency within the last 5 years * if the patient has a history of major haematological, renal, gastrointestinal, hepatic, respiratory, cardiovascular or psychiatric disease or other illness or use of any medications, including over the counter products, which, in the opinion of the investigators would either interfere with the study or potentially cause harm to the volunteer * if the patient has any medical or psychological condition or social circumstances which would interfere with their ability to participate reliably in the trial * if the patient is without access to a telephone * if the patient is currently receiving or intends to receive treatment with an investigational drug within the next 2 months if the patient is currently receiving or intends to receive treatment for binge eating * if the patient currently suffers with severe depression, as indicated by a beck depression inventory score greater than 28

Keywords: obesity bariatric surgery binge eating self help
inspire-cf: an alternative physiotherapy model for children with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the primary aim of the research is to evaluate whether an alternative model of cystic fibrosis (cf) physiotherapy care can produce statistically significant improvements in clinical and patient reported outcomes, and whether this alternative model is economically advantageous and/or sustainable. children randomised to the control group will receive 24-months of current model of cf care at great ormond street hospital (gosh). children randomised to the intervention group will receive 24-months of current model of cf care at gosh plus a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school. the exercise prescription will include aerobic, anaerobic, strength, core conditioning and stretching components. the main objectives of the study are: 1. determine differences, if any, in lung function between the two groups; 2. determine differences, if any, in exercise capacity between the two groups; 3. evaluate cost of care of alternate model of care versus current model of care.


Eligibility criteria:
inclusion criteria: * patients with a documented diagnosis of cystic fibrosis; * male or female aged 6 years or older at baseline and \<17years old at the end of the 2-year study; * currently under the primary care of the gosh cf unit; * able to perform spirometry with a baseline fev1 percentage predicted of 40% or higher, as measured on at least 3 occasions in the previous year, during times of clinical stability (i.e. not during an exacerbation, and not during or within 2 weeks of intravenous antibiotics); * the participant's parent or legal guardian must be able to give informed consent; assent will be sought from all children. exclusion criteria: * patients who have had lung transplantation; * patients listed for lung transplantation; * clinically significant disease or medical condition other than cf or cf-related conditions that in the opinion of the multi-disciplinary clinical team, would compromise the safety of the patient; * orthopaedic impairment that compromises exercise performance; * mental impairment leading to inability to cooperate; * unable to understand both verbal and/or written instructions english. children will need to be able to understand exactly what the physiotherapists are instructing them do, for safe and effective exercise training sessions. information sheets and questionnaires are only available in english; * participants, parents or legal guardians who are unwilling to sign consent to participate in the study. the following criteria will not exclude a child from participating in the study, but based on the hospital's exercise laboratory's infection control protocol, may preclude the participant from cardiopulmonary exercise testing. * patients with methicillin-resistant staphylococcus aureus; * patients with burkholderia cepacia.

Keywords: exercise physiotherapy lung function quality of life
vaccination against influenza pre-discharge in heart failure

Conditions: Heart Failure

Summary: in patients with heart failure (hf), influenza vaccination should be considered to prevent hf hospitalizations. however, vaccination rates among patients with hf are low, in part because of subjective but common concerns about whether patients with such severe disease should be vaccinated. in this randomized, open-label study, we will investigate whether influenza vaccination before discharge in patients stabilized after cardiac decompensation is safe and improves outcomes over a 6-month follow-up period.


Eligibility criteria:
inclusion criteria: * informed consent to participate in the study * hospitalization (unplanned) due to exacerbation (decompensation) of heart failure * planned discharge within the next 48 hours due to completion of hospital treatment * no current (2024/25 season) influenza vaccination. exclusion criteria: * severe post-vaccination reaction during influenza vaccination in any previous influenza season * hypersensitivity to any of the components of the vaccine planned to be administered * discharge to another hospital for continued treatment or discharge to a nursing home * antibiotic therapy among the drugs recommended for taking after hospitalization.

Keywords: heart failure influenza vaccination
multislice computed tomography in cases with facial nerve paralysis due to temporal bone trauma

Conditions: Facial Nerve Paralysis

Summary: facial nerve paralysis is a disfiguring complication which occurs in 7-10 % of temporal bone fractures. the onset of paralysis may be immediate, delayed or undetermined, the latter of which often occurs in unconscious patients with accompanying life-threatening complications.about one fourth has complete paralysis.

facial nerve paralysis might have variable etiologies apart from idiopathic bell's palsy, congenital, infectious, inflammatory, neoplastic, neurological, toxic, iatrogenic and atraumatic causes. surgical intervention is indicated if 90-95% loss of function is seen at the very early period on electroneuronography or if there is axonal degeneration on electromyography lately with no sign of recovery. high-resolution multislice computed tomography of the temporal bone is routinely required for evaluation of traumatic facial paralysis. high-resolution multislice computed tomography is known to be the best method for evaluating the intratemporal course of the facial nerve, but it has some limitations as well. occasionally, the surgeon may encounter facial nerve injuries which have not been revealed in the preoperative computed tomography. there are limited data in recent medical publications evaluating the diagnostic value of temporal bone high-resolution multislice computed tomography in the evaluation of traumatic facial paralysis. therefore, in this study,the investigators will compare the findings of preoperative high-resolution multislice computed tomography with surgical findings to determine the diagnostic value of computed tomography.

Eligibility criteria:
inclusion criteria: * all patients with temporal bone fracture presented with facial nerve paralysis of immediate onset and meet the criteria of facial nerve exploration regardless of age and sex. exclusion criteria: * pregnant women. * unfit patients for surgery. * patients refuse surgical intervention.
anticoagulation regimens in pregnant patients with prosthetic heart valves

Conditions: Pregnancy; Heart; Complications, Valve, Prosthesis

Summary: pregnancy is associated with increased risk of thrombosis among women with mechanical prosthetic heart valves.however, the best anticoagulant treatment strategies for pregnant patients with prosthetic heart valves have been controversial. in this study the investigators wanted to identify the most effective and safe regimen among different anticoagulant regimens.

four different anticoagulant treatment regimens for pregnant patients with prosthetic heart valves have been described. in the first arm warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day which is monitored by weekly anti-xa levels (between 0.7-1.2) during the first trimester and followed by only warfarin after first trimester. in the second arm, if the patient's warfarin consumption is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester combined with enoxaparine in 1mg/kg dose twice a day; adjusted by measurements of anti-xa levels (between 0.5-1) weekly until the end of 12th week of pregnancy . in the third arm warfarin dose is decreased to 4 mg during the first trimester combined with enoxaparine given in a similar manner. if the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy in the 4th arm. all patients are followed by serial transesophageal echocardiography performed at 0,3,6 and 9. months of pregnancy. informed consent is taken from all patients. after delivery the babies are examined by a experinced pediatrician and pediatric cardiologist for any congenital anomalies.

Eligibility criteria:
inclusion criteria: * pregnant patients with prosthetic heart valves exclusion criteria:

Keywords: anticoagulation prosthetic heart valves pregnancy warfarin thrombosis
development of a biological database in the field of operative intensive care

Conditions: Intensive Care in General

Summary: the storage and use of biomaterial samples is an important requirement for accompanying research and the acquisition of new knowledge to improve prognosis and therapy. biobanking is explicitly recommended in official guidelines. in order to preserve the biomaterial, the patient must consent to the removal, transfer and storage of the biomaterial separately from the consent to the register. the biomaterial is taken at times at which a blood or urine sampling takes place anyway in the clinical routine. therefore no additional interventions are necessary.

the storage and use of biomaterial samples is an important requirement for accompanying research and the acquisition of new knowledge to improve prognosis and therapy. biobanking is explicitly recommended in official guidelines. in order to preserve the biomaterial, the patient must consent to the removal, transfer and storage of the biomaterial separately from the consent to the register. the biomaterial is taken at times at which a blood or urine sampling takes place anyway in the clinical routine. therefore no additional interventions are necessary. sample volumes are defined as follows: * peripheral blood: up to a total of 150 ml distributed to a maximum of 10 morning blood samples (approximately 15 ml blood per blood sample) during the inpatient stay in the intensive care unit (fixed times are admission and discharge of the intensive care unit) * urine: a total of up to 200 ml of catheter urine distributed to a maximum of 10 morning withdrawals during inpatient stays in the intensive care unit (defined times are admission and discharge from the intensive care unit)

Eligibility criteria:
inclusion criteria: * patients after admission to the intensive care unit * 18 years or older * signed informed consent exclusion criteria: * no exclusion criteria are formulated with regard to the objective of the register to record intensive care patients in general. patients with multiple comorbidities, organ dysfunctions, and non-compliance for a curatively-intended therapy should also be recorded in the register. a palliative treatment or decision for best supportive care is not an exclusion criterion for registering.
a trial of rad001/capecitabine in refractory gastric cancer

Conditions: Metastatic Gastric Cancer

Summary: capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment of metastatic gastric and colorectal cancer patients. on the basis of capecitabine-based chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the phase i/ii study with all-oral regimen of rad001 with capecitabine for these refractory gastric cancer patients.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically proven gastric cancer patients 2. adequate organ function as defined by the following criteria: a. serum aspartate transaminase (ast; serum glutamic oxaloacetic transaminase (sgot)) and serum alanine transaminase (alt; serum glutamic pyruvic transaminase (sgpt)) ≤ 2.5 x local laboratory upper limit of normal (uln), or ast and alt less than or equal to 5 x uln if liver function abnormalities are due to underlying malignancy b. total serum bilirubin ≤ 3.0 mg/dl c. absolute neutrophil count (anc) ≥1500/µl d. platelets ≥100,000/µl e. hemoglobin ≥9.0 g/dl (may be transfused or erythropoietin treated) f. serum calcium ≤12.0 mg/dl g. serum creatinine ≤1.5 x uln 3. patients with cns metastasis must have stable neurologic function without evidence of cns progression within 8 weeks 4. patients who have failed to at least two previous cytotoxic chemotherapy for advanced gastric cancer (adjuvant treatment will be counted as one regimen if received \< 12 months from the start of experimental treatment) 5. at least one measurable lesion by recist criteria 6. ecog ps 0-2 7. patients with informed consent exclusion criteria: 1. major surgery or radiation therapy within 4 weeks of starting the study treatment. 2. history of or known carcinomatous meningitis, or evidence of symptomatic leptomeningeal disease on screening ct or mri scan. 3. ongoing cardiac dysrhythmias of nci ctcae grade ≥ 2. 4. pregnancy or breastfeeding. 5. prior exposure to the study drug. 6. patients unable to swallow oral medications.

Keywords: gastric cancer refractory metastatic
the role of different imaging methods in the diagnosis of gallbladder polyps

Conditions: Polyp of Gallbladder

Summary: this prospective cohort study is designed to investigate and to compare the diagnostic performance of contrast-enhanced ultrasonography (ceus) and multidetector computed tomography (ct) for gallbladder cholesterol polyps, adenoma and gallbladder cancer.

in this study, investigators aimed to investigate the diagnostic performance of ceus and high resolution ct (hrct) for the preoperative differential diagnostic accuracies of gallbladder polypoid lesions.

Eligibility criteria:
inclusion criteria: * all patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal us. exclusion criteria: * gallbladder polyp with a diameter less than 10 mm. * lesions highly suspected to be cancer due to visible metastasis. * allergy to contrast agents and cannot received ct or ceus examination. * women in pregnancy or lactation.

Keywords: ceus ct gallbladder cholesterol polyps adenoma gallbladder cancer
safety and efficacy of a violet visible light blocking intraocular lens (iol)

Conditions: Cataract

Summary: the purpose of this study is to evaluate the safety and effectiveness of a new investigational modified light transmission monofocal intraocular lens compared to a conventional intraocular lens (iol).

the investigational iol will be found to be safe and effective with respect to visual acuity, color vision, contrast sensitivity and complications and will be similar to results for the za9003 control eyes. complication rates and adverse event rates will be within the fda grid for posterior chamber iols.

Eligibility criteria:
inclusion criteria: * age 18 years of age or older * bilateral cataracts for which phacoemulsification extraction and posterior iol implantation has been planned * visual potential in both eyes of 20/30 snellen or better after cataract removal and iol implantation * preoperative corneal astigmatism of 1.5 diopters or less exclusion criteria: * use of systemic or ocular medications that may affect vision * uncontrolled systemic or recurrent ocular disease * requiring an intraocular lens \ 26.0 diopters * abnormal results with the farnsworth-munsell d-15 and/or ishihara color plates * history of ocular trauma or prior ocular surgery * known pathology that may affect visual acuity or visual field * corneal abnormalities * pupil abnormalities * capsule or zonular abnormalities

Keywords: cataract monofocal intraocular lens acrylic
simultaneous integrated boost (sib)- imrt

Conditions: Carcinoma, Squamous Cell

Summary: the objective of the study is to assess the feasibility of increasing dose of irradiation with imrt using a sib approach over 6 weeks. the primary endpoint of the study will be acute toxicity assessed during treatment and during the first 3 months following the completion of radiotherapy the secondary endpoint will include loco-regional control, disease-free survival, survival and late toxicity at 2 years after completion of radiotherapy

loco-regional failures remain a major concern following irradiation of locally advanced head and neck cancers. this has led radiation oncologists to investigate novel approaches offering better therapeutic indexes. modification of dose fractionation schedules can improve the therapeutic outcome by using accelerated or hyperfractionated regimes -ang, 1990; ang, 1998; fu, 2000; gwozdz, 1997-. intensity modulated radiation therapy (imrt) technique allows the planning and irradiation of different targets at different dose levels in a single treatment session, instead of successive treatment plans. with conventional 2d radiotherapy, both normal tissues and tumors are irradiated with a similar dose per fraction of 1.8-2 gy, whereas with imrt dose gradients are introduced in such a manner that normal tissues receive a much lower dose per fraction.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients with squamous cell carcinoma of the oropharynx, hypopharynx and larynx * stage t2-n0-m0, t2-n1-m0 or t3-n0-m0 * world health organization (who) performance status of 0 or 1 or karnofsky performance status ≥ 70. * provision of written informed consent exclusion criteria: * second primary tumor at the time of diagnosis * previous history of malignant tumor in the last five years except basal cell carcinoma and carcinoma in situ of the cervix * previous treatment with surgery, radiotherapy or chemotherapy for head and neck malignancy * any evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, cardiac, hepatic or renal disease), or psychological disorder * pregnant or lactating women
effects of integrative medicine on infectious respiratory diseases including covid-19

Conditions: Covid19; Influenza A; Respiratory Disease

Summary: the outbreak of the novel coronavirus sars-cov-2 caused a health emergency of international proportions when it was declared by the world health organization (who) in january 2020. since then, the virus has spread internationally and the who has classified the outbreak as a pandemic. in the context of the increasing reporting of this pandemic and the increasing governmental measures to limit or slow down the spread of sars-cov-2 by all means, there is so far little scientific evidence for the effects of a healthy lifestyle on the disease. the aim of this study is to compare the potential of different, possibly protective lifestyles using the example of the covid-19 pandemic. we will conduct an online survey with 3.000 participants using mobile website technology.


Eligibility criteria:
inclusion criteria: - present declaration of consent exclusion criteria: - lack of consent to participate in the study
topical steroid treatment for dry eye

Conditions: Dry Eye

Summary: many patients refer to an oculoplastic or corneal clinic examination due to dry eye symptoms. epidemiologic studies estimate that as many as 15% of the population over 60 years suffer from dry eye. the disease can be treated both topically through several drugs or through mechanical closure of the lacrimal drainage system. in the past decade a few studies demonstrated the efficacy of anti inflammatory treatment on dry eye disease due to the inflammatory process that occurs in it. this treatment rises goblet cell counts but in the meantime elevates the intra ocular pressure and elevates the risk for infections. steroids that cause a lower increase in intraocular pressure have not been thoroughly evaluated in dry eye disease. we with to subjectively and objectively evaluate an fda approved topical steroidal drug in the treatment of dry eye.

30 patients 21 year or older, from both sexes with no previous eyelid or corneal surgeries, refered to our outpatient clinics will be recruited and evaluated. the initial examination will include schirmer1 test, tear break up time test, a full ophthalmologic evaluation and a dry eye questionaire. after signing a concent form patient will be treated with loteprednol etabonate four times a ady for a month, then a second examination will take place. after that and according to necessity patients will be treated with loteprednol etabonate two times daily for another month and return for a follow up examination. intraocular pressure will be evaluated in each follow up visit as well as dry eye symptoms, schirmer 1 test and tear break up time test.

Eligibility criteria:
inclusion criteria: * referral for ophthalmic examination due to dry eye symptoms * ability to sign a concent form exclusion criteria: * former corneal, eyelid or lacrimal gland operations * former orbital chemotherapy or irradiation treatment

Keywords: dry eye inflammatory reaction steroids